Clinical Trial Update: Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating camrelizumab plus apatinib as maintenance therapy in extensive-stage small cell lung cancer; status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Small Cell Lung Carcinoma | Phase 2 | Status: UNKNOWN